EIF2B1

Across TCGA pan-cancer cohorts, EIF2B1 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated EIF2B1 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EIF2B1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF2B1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where EIF2B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.592	0.891	<.001	70	view →
LSCC	DFS	Median	II,III,IV	0.877	0.678	.007	37	view →
PDAC	DFS	Tertile	III,IV	0.481	0.986	.001	31	view →
UCEC	DFS	Quartile	III,IV	1.000	0.300	.020	8	view →
HNSC	DFS	Tertile	III,IV	0.736	0.477	.019	7	view →
OV	DFS	Median	All	0.935	0.646	.032	4	view →
GBM	DFS	Quartile	All	0.667	0.864	.010	2	view →
LUAD	OS	Tertile	III,IV	1.000	0.723	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

EIF2B1–CCRCC (DFS)

Open the CCRCC breakdown →